From: Expression and prognostic significance of lysozyme in male breast cancer
Relapse-free survival (%) | ||||
---|---|---|---|---|
Patient and tumor characteristics | n | 5 years (% ± s.e.) | 10 years (% ± s.e.) | P |
Age | n.s. | |||
<60 | 16 | 100 | 66 ± 27 | |
≥ 60 | 41 | 71 ± 8 | 71 ± 8 | |
Tumor size | n.s. | |||
T1 | 20 | 76 ± 12 | 50 ± 2 | |
T2 | 19 | 94 ± 5 | 94 ± 5 | |
T3-T4 | 18 | 64 ± 13 | - | |
Nodal status | <0.005 | |||
N0 | 32 | 95 ± 4 | 95 ± 4 | |
N+ | 25 | 61 ± 11 | 41 ± 18 | |
Histological grade | n.s. | |||
I | 12 | 100 | - | |
II | 25 | 81 ± 8 | 81 ± 8 | |
III | 20 | 68 ± 12 | 41 ± 18 | |
Lysozyme* | <0.05 | |||
≥ 100 | 25 | 64 ± 11 | 64 ± 11 | |
<100 | 84 | 93 ± 4 | 75 ± 17 |